June 01, 2011
INC Acquires Australian CRO Trident Clinical Research
Raleigh, NC, June 1, 2011 – INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, today announced the acquisition of Trident Clinical Research to expand its clinical trials outsourcing footprint and expertise in Australia, New Zealand and India. Under the terms of the agreement, Trident will become a wholly owned affiliate of INC Research and will operate as Trident Clinical Research, an INC Research company through its offices in Sydney, Brisbane, Melbourne, Adelaide, Auckland and Mumbai. Trident’s operation in Mumbai will increase the reach of INC Research’s already sizeable clinical and data operations located in Gurgaon, India.
“Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” said James Ogle, CEO of INC Research. “Trident has established an exceptional reputation in the region with emerging biotechs to local affiliates of global pharmaceutical companies and major principal investigator units. We are very happy to add them to our team.”
Founded in 1997, Trident has strategically grown to become one of Australia’s largest, and most respected, CROs with more than 100 employees across three countries, a full range of clinical research services and diverse therapeutic experience. With more than 500 clinical studies completed across Phase I to IV, including over 100 Phase I studies, Trident has achieved an outstanding working relationship with key Phase I units in Australia.
Based on data from the Economist Intelligence Unit, Australia offers significant cost advantages, has a highly efficient regulatory system according to timeline indicators and is a desirable location to conduct early phase clinical trials, especially when compared to the USA, UK, Germany, Japan and Singapore. Australia achieves very rapid study timelines without the need for IND or CTA. For these reasons, Australia is becoming a prime destination for conducting first-in-man and early phase clinical studies. Trident has a leading position in designing and reporting Phase I trials as well as managing the advanced Phase I facilities, fully leveraging the streamlined regulatory process in Australia for clinical trials to drive efficiencies for their customer’s projects.
“The R&D opportunities in Australia, New Zealand and India for cost-effective local and global drug development programs are enormous,” said Garth Tierney, managing director and co-founder of Trident Clinical Research, who will assume the role of Regional General Manager, Australasia at INC Research. “We bring to bear the most experienced management team and staff in the region, which underscores INC Research’s on-the-ground capabilities. We look forward to leveraging INC Research’s resources and Trusted Process methodology to enhance our services.”
For more information on INC Research’s clinical trials services in Asia Pacific, please visit www.incresearch.com/asiapac.
About INC Research, LLC
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.
(Source: INC Research)